Literature DB >> 8531026

Central venous catheter infection with Rhodotorula minuta in a patient with AIDS taking suppressive doses of fluconazole.

L Z Goldani1, D E Craven, A M Sugar.   

Abstract

A case of Rhodotorula minuta central venous catheter infection with fungaemia is described in a patient with advanced acquired immunodeficiency syndrome (AIDS), HIV nephropathy, end-stage renal disease requiring haemodialysis, and a permanent Quinton catheter in place for 6 months. At the time of fungaemia, the patient was taking 100 mg fluconazole per os daily for a previous episode of Candida oesophagitis. R. minuta central venous catheter infection with fungaemia was successfully treated with 455 mg total dose amphotericin B (0.6 mg kg-1 day-1) over 25 days without removal of the catheter. In vitro antifungal susceptibility testing for R. minuta revealed a minimum inhibitory concentration to fluconazole of > 100 micrograms ml-1 and to amphotericin B of 1.2 microgram ml-1. Clinically evident fungaemia, even with an unusual organism such as R. minuta, may occur in patients with intravenous catheters, and while the immunosuppressed patient is receiving azole therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8531026     DOI: 10.1080/02681219580000531

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN: 0268-1218


  7 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Activities of available and investigational antifungal agents against rhodotorula species.

Authors:  D J Diekema; B Petroelje; S A Messer; R J Hollis; M A Pfaller
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

3.  Catheter-related sepsis due to Rhodotorula glutinis.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Shen-Wu Ho; Kwen-Tay Luh
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

4.  Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates.

Authors:  Aimee K Zaas; Molly Boyce; Wiley Schell; Barbara Alexander Lodge; Jackie L Miller; John R Perfect
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

5.  Bloodstream Infection of a Cancer Patient by Cystobasidium minutum: A Case Report and Literature Review.

Authors:  Cicero P Inácio; Madi V Diniz; Paulo Sergio R Araújo; Marilane S Barros; Melyna C L Andrade; Reginaldo G Lima-Neto; Danielle Patrícia C Macêdo; Rejane P Neves
Journal:  Mycopathologia       Date:  2020-01-02       Impact factor: 2.574

6.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; H Bijie; D Dzierzanowska; N N Klimko; V Letscher-Bru; M Lisalova; K Muehlethaler; C Rennison; M Zaidi
Journal:  J Clin Microbiol       Date:  2008-11-12       Impact factor: 5.948

Review 7.  Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal.

Authors:  Sofia Costa-de-Oliveira; Acácio G Rodrigues
Journal:  Microorganisms       Date:  2020-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.